筋痙縮の世界市場

筋痙縮の世界市場は2030年までに51億米ドルに達する見込み

2024年に40億米ドルと推定される筋痙縮の世界市場は、2024～2030年の分析期間においてCAGR 4.1%で成長し、2030年には51億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるバクロフェン製剤は、CAGR 5.2%を記録し、分析期間終了時には21億米ドルに達すると予測されます。ボツリヌス毒素製剤セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 7.7%で成長予測

米国の筋痙縮市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 7.7%で推移し、2030年には10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.3%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界の筋痙縮市場- 主要動向と促進要因のまとめ

筋痙縮が医療や調査で注目される理由とは？

筋痙縮は、脳と脊髄間の情報伝達の障害に起因する不随意的な筋肉のこわばりやつっぱりを特徴とする神経疾患です。一般的に、多発性硬化症、脳性麻痺、外傷性脳損傷、脊髄損傷、脳卒中などの基礎疾患の症状として起こる。痙縮は可動性を損ない、慢性疼痛を引き起こし、関節機能を制限し、生活の質を著しく低下させる。その臨床的影響は重症度や基礎疾患によって異なるため、集学的治療や専門的治療に対する需要が高まっています。

痙縮の管理には、薬理学的、理学的、介入的アプローチを組み合わせる必要があります。痙縮の機能的・心理社会的負担に対する認識が高まるにつれ、ヘルスケアプロバイダーは早期診断と統合的な管理計画に重点を移しています。先進的な臨床評価と患者報告アウトカムツールは、同定と分類を改善し、オーダーメイドの介入を可能にしています。随意運動を維持しながら筋緊張を最適化し、拘縮を予防する個別化された治療プロトコルの需要が高まっています。

痙縮に対処するために一般的に使用されている治療法は？

現在の治療法には、バクロフェン、チザニジン、ジアゼパムなどの経口薬があり、中枢神経系の経路を通じて筋緊張を調節することで効果を発揮します。多くの患者に有効ですが、これらの薬剤は鎮静作用や全身性の副作用を引き起こすことが多く、長期間の使用には限界があります。局所の痙縮や重度の痙縮に対しては、特定の筋群を標的としてボツリヌス毒素の筋肉内注射が頻繁に行われます。この方法は、特に局所性痙縮や分節性痙縮において、全身的な影響が少なく、より正確なコントロールが可能です。

より抵抗性の強い症例では、手術で植え込んだポンプを介して髄液に直接薬剤を投与する髄腔内バクロフェン療法が用いられます。この方法では、全身への曝露を抑えながら、強力な症状コントロールが可能です。補助療法としては、可動域を維持し、可動性を改善するための理学的リハビリテーション、装具によるサポート、ストレッチプログラムなどがあります。神経調節、標的神経毒、遺伝子ベースの治療などの新しい治療法は、より長期的で選択的な痙縮管理を行うために研究されています。

市場力学に影響を与える患者ニーズとヘルスケア課題とは？

筋痙縮の患者は、神経科医、リハビリテーション医、理学療法士、介護者を含む長期的な連携ケアを必要とすることが多いです。この疾患は、特に複雑な神経障害を持つ患者において、過小診断や誤診が多いです。農村部や資源の乏しい環境では、専門的なケアや治療注射へのアクセスが制限されることがあります。治療アドヒアランスは、薬剤の副作用、注射による疲労、高度な選択肢の認知度の低さによっても影響を受ける。

小児および老年人口には特有の課題があります。脳性麻痺の小児は、変形を予防し機能を改善するために早期の介入が必要であり、脳卒中に関連した痙縮を有する高齢者は、さらなる併存疾患や虚弱に直面する可能性があります。ヘルスケアシステムは、遠隔医療によるフォローアップやウェアラブルデバイスによる遠隔モニタリングなど、非侵襲的で在宅ベースのサポートモデルをますます重視するようになっています。保険償還の枠組みや治療へのアクセスも地域によって大きく異なり、製品の採用や患者の転帰に影響を与えています。

筋痙縮市場の成長はいくつかの要因によって牽引される...

筋痙縮市場の成長は、いくつかの要因によってもたらされます。脳卒中や多発性硬化症などの神経疾患の有病率が上昇し、患者数が増加しています。神経毒治療、植え込み型ポンプ、リハビリ技術の進歩により、治療の選択肢が広がっています。医師や介護者の意識の高まりにより、診断やケアの継続性が向上しています。集学的ケアモデルと個別化医療の統合が、より良い長期管理を支えています。ニューロモジュレーション、再生医療、ドラッグデリバリーの技術革新に関する研究が拡大し、次世代の治療法の提供が期待されます。ヘルスケア支出の増加と患者の支持は、痙縮に焦点を当てたケアとイノベーションへの投資をさらに促進しています。

セグメント

薬剤タイプ（バクロフェン製剤、ボツリヌス毒素製剤、ジアゼパム製剤、ダントロレンナトリウム製剤、その他の薬剤タイプ）、投与経路（経口投与、筋肉内投与、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

• Abbott Laboratories
• Allergan plc（AbbVie）
• Acorda Therapeutics
• ANI Pharmaceuticals
• Beximco Pharmaceuticals
• Boston Scientific Corporation
• Elite Pharmaceuticals
• Endo Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd
• Ipsen Pharma
• Johnson & Johnson（Ethicon/Janssen）
• Mallinckrodt Pharmaceuticals
• Merz Pharmaceuticals GmbH
• Medtronic plc
• Neurocrine Biosciences
• Novartis AG
• Revance Therapeutics
• Saol Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Muscle Spasticity Market to Reach US$5.1 Billion by 2030

The global market for Muscle Spasticity estimated at US$4.0 Billion in the year 2024, is expected to reach US$5.1 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Baclofen Drug, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Botulinum Toxin Drug segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.7% CAGR

The Muscle Spasticity market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Muscle Spasticity Market - Key Trends & Drivers Summarized

Why Is Muscle Spasticity Receiving Increased Medical and Research Attention?

Muscle spasticity is a neurological condition characterized by involuntary muscle stiffness or tightness resulting from disrupted communication between the brain and spinal cord. It commonly occurs as a symptom of underlying disorders such as multiple sclerosis, cerebral palsy, traumatic brain injury, spinal cord injury, and stroke. Spasticity can impair mobility, cause chronic pain, limit joint function, and significantly reduce quality of life. Its clinical impact varies by severity and underlying condition, prompting rising demand for multidisciplinary care and specialized treatment.

Managing spasticity requires a combination of pharmacologic, physical, and interventional approaches. As awareness grows regarding the functional and psychosocial burden of spasticity, healthcare providers are shifting focus toward early diagnosis and integrated management plans. Advanced clinical assessments and patient-reported outcome tools are improving identification and classification, enabling tailored interventions. Demand is increasing for personalized treatment protocols that optimize muscle tone while preserving voluntary movement and preventing contractures.

Which Therapies Are Commonly Used to Address Spasticity?

Current treatment options include oral medications such as baclofen, tizanidine, and diazepam, which work by modulating muscle tone through central nervous system pathways. While effective in many patients, these drugs often cause sedation or systemic side effects, limiting long-term use. For localized or severe spasticity, intramuscular botulinum toxin injections are frequently administered to target specific muscle groups. This approach allows more precise control with fewer systemic effects, especially in focal or segmental spasticity.

In more resistant cases, intrathecal baclofen therapy is used to deliver medication directly into the spinal fluid via a surgically implanted pump. This method enables strong symptom control with reduced systemic exposure. Adjunct therapies include physical rehabilitation, orthotic support, and stretching programs to maintain range of motion and improve mobility. Emerging treatments, including neuromodulation, targeted neurotoxins, and gene-based therapies, are being explored to provide longer-lasting and more selective spasticity management.

What Patient Needs and Healthcare Challenges Influence Market Dynamics?

Patients with muscle spasticity often require long-term, coordinated care that involves neurologists, physiatrists, physical therapists, and caregivers. The condition is frequently underdiagnosed or mischaracterized, particularly in patients with complex neurological disorders. Access to specialized care and therapeutic injections can be limited in rural or low-resource settings. Treatment adherence is also affected by drug side effects, injection fatigue, and limited awareness of advanced options.

Pediatric and geriatric populations present unique challenges. Children with cerebral palsy need early intervention to prevent deformities and improve function, while older adults with stroke-related spasticity may face additional comorbidities and frailty. Healthcare systems are increasingly emphasizing non-invasive and home-based support models, including telemedicine follow-ups and wearable devices for remote monitoring. Reimbursement frameworks and therapy access also vary widely by region, influencing product adoption and patient outcomes.

Growth in the Muscle Spasticity Market Is Driven by Several Factors…

Growth in the muscle spasticity market is driven by several factors. Rising prevalence of neurological conditions, including stroke and multiple sclerosis, is increasing the patient base. Advancements in neurotoxin therapies, implantable pumps, and rehabilitation technologies are expanding treatment options. Greater awareness among physicians and caregivers is improving diagnosis and care continuity. Integration of multidisciplinary care models and personalized medicine supports better long-term management. Expanding research into neuromodulation, regenerative medicine, and drug delivery innovations is expected to offer next-generation therapies. Increased healthcare spending and patient advocacy are further encouraging investment in spasticity-focused care and innovation.

SCOPE OF STUDY:

The report analyzes the Muscle Spasticity market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug, Other Drug Types); Administration Route (Oral Administration, Intramuscular Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• Allergan plc (AbbVie)
• Acorda Therapeutics
• ANI Pharmaceuticals
• Beximco Pharmaceuticals
• Boston Scientific Corporation
• Elite Pharmaceuticals
• Endo Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd
• Ipsen Pharma
• Johnson & Johnson (Ethicon/Janssen)
• Mallinckrodt Pharmaceuticals
• Merz Pharmaceuticals GmbH
• Medtronic plc
• Neurocrine Biosciences
• Novartis AG
• Revance Therapeutics
• Saol Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Muscle Spasticity - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Neurological Disorders Drives Demand for Muscle Spasticity Treatment Options
  • Increased Diagnosis of Cerebral Palsy, Multiple Sclerosis, and Stroke Aftereffects Throws Spotlight on Spasticity Management
  • Advancements in Neurorehabilitation and Physiotherapy Expand Non-Pharmacological Treatment Avenues
  • Pharmaceutical Innovation in Muscle Relaxants, Botulinum Toxin, and Antispastic Agents Fuels Market Growth
  • Growing Aging Population Globally Strengthens Incidence of Post-Stroke and Age-Related Spasticity
  • Integration of Multidisciplinary Care Models Enhances Treatment Outcomes and Patient Adherence
  • Regulatory Approvals of Long-Acting Injectables and Neuromodulators Boost Adoption of Novel Therapies
  • Technological Progress in Implantable Devices and Nerve Stimulation Systems Opens Non-Drug Management Options
  • OEM Development of Digital Mobility Aids and Wearables Supports Real-Time Monitoring of Muscle Stiffness
  • Increasing Awareness Among Healthcare Providers Improves Referral and Diagnosis Rates in Early Stages
  • Emergence of Robotic-Assisted Therapy Devices Encourages Investment in Advanced Physical Treatment
  • Patient Education and Advocacy Groups Strengthen Demand for Tailored and Multimodal Interventions
  • Focus on Quality of Life Improvements Promotes Combined Use of Drug, Therapy, and Lifestyle Approaches
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Muscle Spasticity Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Muscle Spasticity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Muscle Spasticity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Muscle Spasticity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Baclofen Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Baclofen Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Baclofen Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Botulinum Toxin Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Botulinum Toxin Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Botulinum Toxin Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Diazepam Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Diazepam Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Diazepam Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Dantrolene Sodium Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Dantrolene Sodium Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Dantrolene Sodium Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Intramuscular Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• JAPAN
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• CHINA
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• EUROPE
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Muscle Spasticity by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Muscle Spasticity by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• FRANCE
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• GERMANY
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Muscle Spasticity by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Muscle Spasticity by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• INDIA
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Muscle Spasticity by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Muscle Spasticity by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Muscle Spasticity by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Muscle Spasticity by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030
• AFRICA
  • Muscle Spasticity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Muscle Spasticity by Drug Type - Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Muscle Spasticity by Drug Type - Percentage Breakdown of Value Sales for Baclofen Drug, Botulinum Toxin Drug, Diazepam Drug, Dantrolene Sodium Drug and Other Drug Types for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Muscle Spasticity by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Muscle Spasticity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Muscle Spasticity by Administration Route - Oral Administration, Intramuscular Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Muscle Spasticity by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Intramuscular Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION